Related Experiment Video
Updated: Jun 25, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Clinical correlation of multiple biomarkers for risk assessment in patients with acute coronary syndrome
V S Narain1, Nishant Gupta, Rishi Sethi
1Department of Cardiology, King George Medical University, Lucknow.
Insights
Elevated troponin-T, high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) improve cardiovascular event prediction in acute coronary syndrome (ACS) patients. Combining these biomarkers offers critical prognostic insight for ACS assessment.
Area of Science:
- Cardiology
- Biomarker Research
- Acute Coronary Syndromes
Background:
- Biochemical markers are crucial for predicting cardiovascular events in non-ST-segment elevation acute coronary syndrome (ACS).
- Assessing the prognostic value of troponin-T, hs-CRP, and NT-pro-BNP is vital for patient management.
Purpose of the Study:
- To evaluate the independent and combined prognostic value of troponin-T, hs-CRP, and NT-pro-BNP.
- To assess their impact on the Thrombolysis In Myocardial Infarction (TIMI) risk score and short-term prognosis in ACS patients.
Main Methods:
- Analysis of troponin-T, hs-CRP, and NT-pro-BNP levels in 80 ACS patients (unstable angina/NSTEMI).
- Correlation of biomarker elevation with TIMI risk score and 30-day major adverse cardiac events.
- Stratification of risk based on individual and combined biomarker levels.
Main Results:
- hs-CRP levels were higher in patients with angina; NT-pro-BNP levels were higher in patients with heart failure.
- Troponin-T was highest in patients with both angina and heart failure.
- Elevated hs-CRP and troponin-T correlated with re-ischemia; NT-pro-BNP correlated with heart failure development.
- Combined elevation of any two biomarkers indicated intermediate risk; all three indicated high risk per TIMI score.
- Elevated levels of all three biomarkers significantly increased the 30-day risk of cardiovascular death.
Conclusions:
- The combination of NT-pro-BNP, hs-CRP, and troponin-T provides significant prognostic information.
- These biomarkers enhance the assessment of patients with ACS.
- Combined biomarker analysis aids in predicting short-term adverse cardiac events.
Objective:
Biochemical markers are useful for the prediction of future cardiovascular events in patients with non-ST-segment elevation acute coronary syndrome (ACS). The independent as well as the combined prognostic value of elevated troponin-T, high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) on the Thrombolysis In Myocardial Infarction (TIMI) risk score and on the short-term prognosis were evaluated in a cohort of ACS patients.
Methods And Results:
In an unselected, heterogeneous group of 80 patients with ACS (i.e., unstable angina [USA] or non-ST-elevation myocardial infarction [NSTEMI]), the levels of troponin-T, hs-CRP, and NT-pro-BNP were analyzed. The correlation between elevation of different biomarkers with TIMI risk score and their impact on 30-day major adverse cardiac events was sought. The levels of hs-CRP were significantly higher in patients who had angina as their predominant complaint (3.67 mg/dl vs. 1.67 mg/dl: p < 0.01), while levels of NT-pro-BNP was higher in those patients who had any element of heart failure at presentation (2616.39 pg/ml vs. 1068.3 pg/ml; p < 0.01). Troponin-T was highest in patients who had an element of both heart failure and angina at presentation (p < 0.01). The TIMI risk score expectedly had a positive and strong correlation with elevated troponin-T, but had no correlation with elevation of hs-CRP and NT-pro-BNP in isolation. However, when any two biomarkers were elevated, the patients were in the intermediate risk group as per TIMI risk score irrespective of troponin-T-elevation. When all the three biomarkers were elevated, the risk equaled the high-risk category of TIMI risk score. Elevated hs-CRP (3.40 mg/dl vs. 1.38 mg/dl; p < 0.001) and troponin-T (2.37 ng/ml vs. 1.23 ng/ml; p < 0.001) at baseline correlated independently with the occurrence of re-ischemia, while elevated NT-pro-BNP alone correlated significantly with the development of heart failure within 30 days of follow-up (4247.76 pg/ml vs. 1210.86 pg/ml; p < 0.01). The highest risk of death from any cardiovascular cause within 30 days of follow-up was significantly higher when all the three biomarkers were elevated.
Conclusion:
The use of NT-pro-BNP, hs-CRP, and troponin-T in combination appears to add critical prognostic insight to the assessment of patients with ACS.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management